Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

Fig. 4

Effect of P021 on reversal of dendritic and synaptic deficits in 3 × Tg-AD mice at 9 months posttreatment. After 9 months of treatment, 3 × Tg-AD mice fed a P021 diet (Tg-AD-P021) and vehicle-treated (Tg-AD vh) and wild-type (WT) controls mice were euthanized and the expressions of PSD-95, NR1, and MAP2 were studied by immunohistochemical staining. Immunohistochemical staining of: a PSD-95 in CA1 (stratum radiatum and stratum pyramidae), CA3 (stratum oriens, stratum radiatum, and stratum pyramidae), dentate gyrus (DG; entire area), and the parietal cortex (all six layers); b NR1 in CA3; and c MAP2 in DG, CA3, and parietal cortex. d Quantification of immunohistochemical staining. 3 × Tg-AD-vh showed a decrease in the expression of PSD-95 and NR1, and P021 rescued this deficit in 3 × Tg-AD mice. *p < 0.05, **p < 0.01, by one-way ANOVA post-hoc test. Scale bar = 100 μm. WT, n = 5; 3 × Tg-AD-vh, n = 5; 3 × Tg-AD-P021, n = 5. Each maximum projection picture to be analyzed was converted to greyscale and each area to be analyzed was selected, the threshold was adjusted, and the mean pixel intensity of the region of interest was quantified. Quantification is shown as mean ± SD

Back to article page